Prediction of human pharmacokinetics in 2013 and beyond

Drug Metabolism and Disposition

Volumn 41, Issue 12, 2013, Pages 1973-1974

  Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE;

ARTICLE; CYP2B6 GENE; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG INDUSTRY; DRUG INTERACTION; DRUG METABOLISM; DRUG UPTAKE; ENZYME ACTIVATION; IN VITRO STUDY; IN VIVO STUDY; LIVER METABOLISM; LIVER MICROSOME; MEDICAL RESEARCH; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84888614834     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.055376     Document Type: Article

References (17)

1. Blobaum AL, Bridges TM, Byers FW, Turlington M, Mattmann M, Morrison RD, Mackie J, Lavreysen H, Bartolome JM, MacDonald GJ, et al. (2013) Hetertropic activity of P450 3A by a positive allosteric modulator of metabotrophic glutamate receptor 5: In vitro to in vivo translation and potential impact on clinicality relevant drug-drug interactions. Drug Metab Dispos 41:2066-2075.
2. Callegari E, Kalgutkar AS, Leung LY, Obach RS, Plowchalk DR, and Tse S (2013) Drug metabolites as cytochrome P450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development. Drug Metab Dispos 41:2047-2055.
3. Chan T, Yu H, Moore A, Khetani S, and Tweedie DJ (2013) Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab Dispos 41:2024-2032.
4. Di L, Feng B, Goosen TC, Lai Y, Steyn SJ, Varma MV, and Obach RS (2013a) A perspective on the prediction of drug disposition attributes in drug research and development. Drug Metab Dispos 41:1975-1993.
5. Di L, Atkinson K, Orozco CC, Funk C, Zhang H, McDonald TS, Tan B, Lin J, Chang C, and Obach RS (2013b) In vitro-in vivo correlation for low clearance compounds using hepatocyte relay met. Drug Metab Dispos 41:2018-2023.
6. Frederick CB and Obach RS (2012) Metabolites in Safety Testing: "MIST" for the clinical pharmacologist. Clin Pharmacol Therap 87:345-350.
7. Jones HM, Barton HA, Lai YA, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, and Galetin A, et al. (2012) Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug Metab Dispos 40:1007-1017.
8. Karlsson FH, Bouchene S, Hilgendorf C, Dolgos H, and Peters SA (2013) Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and development. Drug Metab Dispos 41:2033-2046.
9. Kikuchi R, de Morais SM, and Kalvass JC (2013) In vitro P-gp efflux ratio can predict the in vivo brain penetration regardless of BDDCS class. Drug Metab Dispos 41:2012-2017.
10. Lutz JD, Vandenbrink BM, Babu NK, Nelson WL, Kunze KL, and Isoherranen N (2013) Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for prediction of multiple time-dependent inhibitor systems. Drug Metab Dispos 41:2056-2065.
11. Ménochet K, Kenworthy KE, Houston JB, and Galetin A (2012) Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. J Pharmacol Exp Ther 341:2-15.
12. Parker AJ and Houston JB (2008) Rate-limiting steps in hepatic drug clearance: comparison of hepatocellular uptake and metabolism with microsomal metabolism of saquinavir, nelfinavir, and ritonavir. Drug Metab Dispos 36:1375-1384.
13. Shardlow C, Generaux G, Patel A, Tai G, Tran T, and Bloomer J (2013) Impact of physiologically-based pharmacokinetic modelling and simulation in drug development. Drug Metab Dispos 41:1994-2003.
14. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
15. Xu C, Quinney SK, Guo Y, Hall SD, Yi L, and Desta Z (2013) CYP2B6 pharmacogenetics-based in vitro-in-vivo extrapolation (VIVE) of efavirenz clearance by PBPK modelling. Drug Metab Dispos 41:2004-2011.
16. Yabe Y, Galetin A, and Houston JB (2011) Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug Metab Dispos 39:1808-1814.
17. Zamek-Gliszczynski MJ, Lee CA, Poirer A, Benzt J, Ellens H, Ishikawa T, Jamei M, Kalvass JC, Nagar S, and Pang KS, et al. (2013) ITC recommendations for transporter kinetic parameter estimation and translational modelling of transport-mediated PK and DDIs in humans. Nature 94: 64-79.